$-0.07
(Market cap
$147 Mln
Recently Viewed
Clear AllMarket cap
$147 Mln
Revenue (TTM)
$114 Mln
P/E Ratio
--
P/B Ratio
218.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-12.8 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
3.3
Debt to Equity
-1.2
Book Value
$--
EPS
$0
Face value
--
Shares outstanding
38,398,354
CFO
$-937.90 Mln
EBITDA
$-858.53 Mln
Net Profit
$-1,538.99 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Agenus (AGEN)
| 22.3 | 15.0 | 35.2 | 32.9 | 36.5 | 4.8 | 1.1 |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Agenus (AGEN)
| 14.6 | 226.9 | -64.8 | -25.5 | 1.3 | -21.9 | 71.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Agenus (AGEN)
|
3.8 | 147.5 | 114.2 | 0.1 | 53.6 | -0 | -- | 218.6 |
| 74.8 | 10,475.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.8 | 18.4 | |
| 220.9 | 13,649.0 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 43.7 | 11,095.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.7 | 5.1 | |
| 87.6 | 11,613.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 266.0 | 7,831.1 | 389.1 | 204.8 | 41.5 | 18.9 | 38.9 | 6.4 | |
| 513.7 | 11,844.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.7 | |
| 417.5 | 11,924.8 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.2 | 19.9 | |
| 99.0 | 7,822.0 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 324.2 | 9,029.2 | 0.0 | -303.3 | -- | -45.8 | -- | 10.3 |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the... identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Read more
Founder, Executive Chairman & CEO
Dr. Garo H. Armen Ph.D.
Founder, Executive Chairman & CEO
Dr. Garo H. Armen Ph.D.
Headquarters
Lexington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Agenus Inc (AGEN) is $3.84 (NASDAQ) as of 01-May-2026 16:00 EDT. Agenus Inc (AGEN) has given a return of 36.5% in the last 3 years.
Since, TTM earnings of Agenus Inc (AGEN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
964.40
|
-0.41
|
|
2024
|
-0.27
|
-0.19
|
|
2023
|
-0.07
|
-0.11
|
|
2022
|
-0.16
|
-0.64
|
|
2021
|
-1.63
|
0.81
|
The 52-week high and low of Agenus Inc (AGEN) are Rs 7.34 and Rs 2.70 as of 03-May-2026.
Agenus Inc (AGEN) has a market capitalisation of $ 147 Mln as on 01-May-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Agenus Inc (AGEN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.